Development and translation of histotripsy: current status and future directions.
Development and translation of histotripsy: current status and future directions.
复制标题
DOI：
10.1097/mou.0000000000000001
复制
发表时间：
2014-01
影响因子：
2.5
通讯作者：
Roberts WW
中科院分区：
文献类型：
--
作者：
Roberts WW
1)概述组织摧毁术的初步发展，这是一种非侵入性图像引导聚焦超声技术，可机械均匀化靶组织; 2）描述针对泌尿外科应用的临床前转化研究结果。组织破坏组织消融基于在体内目标点处的声空化的启动和控制。这种独特的机械作用机制与传统的热消融方式不同。组织摧毁术的特征（非热、无创、高精度、实时监测/反馈、组织液化）促使人们评估该技术作为许多器官和疾病过程的潜在消融治疗。正在进行的将组织碎石术应用于良性前列腺增生（BPH）、前列腺癌、肾肿块和肾结石的临床前模型的研究工作，增强了对空化生物效应的理解，改进了治疗系统，提高治疗效率的策略，并启动了一项初步的人体临床试验，以评估组织碎石术治疗BPH的安全性。
1) to outline the initial development of histotripsy, a non-invasive image guided focused ultrasound technology that mechanically homogenizes targeted tissues and 2) to describe the results of pre-clinical translational research directed towards urologic applications. Histotripsy tissue ablation is based on initiation and control of acoustic cavitation at a target point within the body. This unique mechanical mechanism of action is distinct when compared to conventional thermal ablative modalities. Features of histotripsy (non-thermal, noninvasive, high precision, real-time monitoring/feedback, tissue liquefaction) have prompted assessment of this technology as a potential ablative therapy for a number of organs and disease processes. Ongoing research efforts to apply histotripsy to preclinical models of benign prostatic hyperplasia (BPH), prostate cancer, renal masses, and renal calculi have resulted in enhanced understanding of cavitation bioeffects, refinement of treatment systems, strategies to enhance treatment efficiency, and initiation of a pilot human clinical trial to assess the safety of histotripsy for BPH therapy.